Top Drugs in 2025:

Lung cancer remains one of the deadliest cancers globally. But in 2025, immune checkpoint inhibitors are significantly improving survival, especially in advanced NSCLC patients.

  • Nivolumab + Ipilimumab: CheckMate-9LA shows over 40% 2-year survival rate

  • Atezolizumab: Approved as adjuvant therapy in early-stage NSCLC

  • Tislelizumab: Shows promise in Asian populations

2025 Data Insight:

“Immunotherapy increased 3-year survival in NSCLC patients to over 36%, compared to 22% with chemotherapy alone.”
Source: Lancet Oncology, 2025

Best Candidates:

  • Patients with PD-L1 expression ≥1%

  • Advanced-stage, chemotherapy-intolerant patients

  • Those seeking improved quality of life in metastatic disease

References:

  • CheckMate Trials Update: Immunotherapy in Lung Cancer – Lancet Oncology, 2025

  • Atezolizumab in Early-Stage NSCLC – JAMA Oncology, 2025

  • Real-world outcomes of Tislelizumab in Asia-Pacific NSCLC patients – Cancer Immunology Research, 2025